Reader’s guide · First edition · September 2026 · Revised September 15, 2026
Living with a GLP-1
Side effects, muscle, meals, surgery, travel, and stopping: the year after the first injection
Semaglutide and tirzepatide work by changing how you eat and how your gut moves, and the side effects are the same mechanism felt from the inside. Most are predictable, most peak at each dose increase, and most can be managed with habits rather than more drugs. This guide covers the first year: getting through titration, protecting muscle while the scale drops, eating in a way that suits the drug, what to tell a surgeon, how to travel with a pen, and what actually happens when you stop.
Who this is for
Written for adults who have been prescribed semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) by a licensed prescriber. The advice is general and follows the prescribing information and clinical guidance; your prescriber's instructions take precedence. It is not medical advice.
Both drugs start at a dose that does little for weight and exists only to let the gut adapt. Each step up restarts the adaptation. The pattern is consistent: side effects rise in the week after an increase, then fade over two to three weeks. The labeled minimum between steps is four weeks, but there is no maximum, and many people do better holding a dose for eight.
| Drug | Start | Steps | Maintenance |
|---|---|---|---|
| Semaglutide (Wegovy) | 0.25 mg weekly for 4 weeks | 0.5, 1, 1.7 mg, each held at least 4 weeks | 2.4 mg (1.7 mg if 2.4 is not tolerated) |
| Semaglutide (Ozempic) | 0.25 mg weekly for 4 weeks | 0.5 mg, then 1 mg | 1 or 2 mg |
| Tirzepatide | 2.5 mg weekly for 4 weeks | 5, 7.5, 10, 12.5 mg, each at least 4 weeks | 5, 10, or 15 mg |
The right maintenance dose is the lowest one that keeps working. Stopping the climb early is not failure; it is the label.
- If a step is rough, ask to hold it longer or drop back one step. Both are within the label.
- Missed dose: semaglutide within 5 days, tirzepatide within 4 days, then resume the schedule. Beyond that, skip it. Never take two doses within three days.
- Judge the drug at a treatment dose after eight weeks, not on the starting month.
| Symptom | Why | What helps |
|---|---|---|
| Nausea | Slowed stomach emptying and brain signaling; worst after dose increases | Smaller meals, stop at the first sign of fullness, low fat, cold or bland food, ginger, eat slowly, do not lie down after eating, and do not push through to finish a plate |
| Vomiting | Overfull stomach on a slowed system | Same as nausea; if it lasts more than a day or you cannot keep fluids down, call: dehydration and kidney injury are the risk |
| Constipation | Slower transit, less food and water | Fluids first, then soluble fiber, then a daily osmotic laxative (polyethylene glycol or magnesium) if needed; walk daily |
| Diarrhea | Common early, usually brief | Hydrate, bland food, avoid sugar alcohols; call if it persists past a few days |
| Reflux and burping | Food sitting longer | Smaller meals, no late dinners, elevate the head of the bed, avoid carbonated drinks and fatty food |
| Sulfur burps | Delayed emptying of protein and fat | Smaller portions of both; simethicone can help |
Call the same day for
Severe, persistent abdominal pain, especially radiating to the back (pancreatitis). Pain under the right ribs with fever or yellowing (gallbladder). Vomiting or diarrhea that stops you keeping fluids down for a day (dehydration and kidney injury). A racing heart, dizziness on standing, or very little urine.
Rapid weight loss of any kind takes lean mass with it, and in the semaglutide trials roughly a quarter to two-fifths of the weight lost was lean tissue. That is similar to diet-induced loss, not a special effect of the drug, but the amounts are larger because the losses are larger. Two habits change the ratio.
- Protein
- 1.2 to 1.6 grams per kilogram of body weight per day, spread over the day, with 25 to 40 grams at each meal. Appetite suppression makes this the first thing to slip; plan it rather than hope for it.
- Resistance training
- Two or three sessions a week of progressive loading, full body. Walking is good for everything else and does not protect muscle.
- Rate
- Faster is not better. Weight loss above about 1% of body weight per week takes proportionally more muscle.
- Bone
- Weight-bearing exercise, calcium, and vitamin D. Bone density falls with large weight loss too.
- Prioritize protein first at each meal, then vegetables, then whatever else fits.
- Liquid protein (milk, yogurt, shakes) counts and is easier on a nauseated stomach.
- Hair shedding three to six months in is common with rapid loss, usually temporary, and improves with adequate protein and time.
- Three small meals and a snack beats two large ones. The stomach empties slowly; volume is the enemy.
- Fat and fried food sit longest and cause the most nausea. Keep them small, especially in the week after a dose increase.
- Alcohol: tolerance drops, hypoglycemia risk rises if you also take insulin or a sulfonylurea, and it worsens reflux. Many people simply lose interest.
- Water: a target of two to three liters a day, sipped, because thirst signaling fades with appetite.
- Eating out: order a starter as a main, box half before you begin, and stop at fullness. The old finish-the-plate reflex is what causes vomiting on these drugs.
- Sugar alcohols and very high-fiber bars cause gas and diarrhea on a slowed gut.
Food noise
The quiet most people notice within days is the drug's central effect on appetite and food reward. It is real, it is the point, and it fades when the drug stops. Use the quiet to build habits that will still be there afterward.
- Surgery and sedation
- Slowed stomach emptying raises the risk of inhaling stomach contents under anesthesia. Tell every surgeon, dentist, and endoscopist. Current guidance ranges from holding the weekly dose for a week before an elective procedure to a 24-hour liquid diet; the anesthesia team decides. Do not stop the drug without telling them.
- Insulin and sulfonylureas
- Hypoglycemia risk rises; those doses usually need lowering when the GLP-1 starts and at each step. Keep glucose tablets on hand.
- Oral medicines
- Slowed emptying can delay absorption of pills. Most do not matter; levothyroxine, warfarin, and narrow-margin drugs should be monitored.
- Oral contraceptives
- Tirzepatide reduces their absorption for four weeks after starting and after each dose increase. Add a barrier method or switch to a non-oral method during those windows.
- Pregnancy
- Not for use. Semaglutide should be stopped at least two months before a planned pregnancy; discuss timing for tirzepatide with your prescriber.
- Mood
- The labels advise watching for depression or suicidal thoughts. The large trials have not shown an increase, but report any change.
- Thyroid
- Do not use with a personal or family history of medullary thyroid carcinoma or MEN 2. Report a neck lump, hoarseness, or trouble swallowing.
Travel, storage, and supply9
| Product | Refrigerated | After first use, up to 86 °F (30 °C) |
|---|---|---|
| Ozempic pen | Until first use | 56 days |
| Wegovy pen | Until use | 28 days (single-dose pens) |
| Zepbound and Mounjaro pens | Until use | 21 days (single-dose pens) |
| Zepbound vials | Until use | 21 days |
- Carry pens in hand luggage in an insulated pouch. Never checked, never in a hot car, never frozen.
- Time zones: keep the same day of the week; a few hours' shift does not matter.
- Take the prescription label and a letter for international travel; sharps and pens are permitted in carry-on with medication.
- Shortages and switches: do not restart at a high dose after a gap of more than two weeks; ask about re-titrating.
- Never split, share, or buy a pen from anyone but a pharmacy. Counterfeit pens have been found in the supply chain.
Weight loss slows and then stops, usually between months 9 and 15, at a new set point the drug is holding. That is a plateau, not a failure, and pushing the dose further past it rarely moves it much. The larger question is what happens if the drug stops.
Of the weight lost on semaglutide 2.4 mg was regained within a year of stopping in the STEP 1 extension
Regained in a year after tirzepatide was withdrawn in SURMOUNT-4; those who continued kept losing
- These are chronic-disease drugs in the trials' design. Plan for maintenance at the lowest effective dose, not a course.
- If stopping is the plan, taper with your prescriber, and expect appetite to return within weeks; the habits from months of quiet are what you keep.
- Weight regain after stopping is the drug wearing off, not a personal failure, and restarting works.
Compounded versions
The shortage that allowed compounded copies of both drugs ended in 2025. What changes when the drug comes from a vial rather than a pen, and how to read the label, is covered in the Society's guide to compounded tirzepatide and in the handling guide.
References
- 1.Wegovy and Ozempic (semaglutide) prescribing information. Novo Nordisk. Current revisions.
- 2.Zepbound and Mounjaro (tirzepatide) prescribing information. Eli Lilly and Company. Current revisions. https://pi.lilly.com/us/zepbound-uspi.pdf
- 3.Wharton S, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14-19.
- 4.Gorgojo-Martínez JJ, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145.
- 5.Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1), including body-composition substudy. N Engl J Med. 2021;384(11):989-1002.
- 6.Conte C, et al. Is weight loss-induced muscle mass loss clinically relevant? JAMA. 2024;332(1):9-10.
- 7.Joshi GP, et al. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. 2023; and the 2024 multi-society clinical practice guidance on GLP-1 agonists and elective procedures.
- 8.Wang W, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176.
- 9.Storage and in-use periods: Ozempic, Wegovy, Zepbound, and Mounjaro prescribing information (patient instructions for use). Current revisions.
- 10.Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
- 11.Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48.